Phase 3 Clinical Trials With Primary Completion Dates in August 2025
This is a list of Phase 3 trials with primary completion dates in August 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| BLTE | Belite Bio, Inc | 2025-08-01 | Phase 3 | NCT05244304 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease |
| ETNB | 89bio, Inc. | 2025-08-01 | Phase 3 | NCT05852431 | To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia |
| GNLX | Genelux Corporation | 2025-08-01 | Phase 3 | NCT05281471 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
| HRMY | Harmony Biosciences Holdings, Inc. | 2025-08-01 | Phase 3 | NCT05458128 | A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients with Idiopathic Hypersomnia |
| QNCX | Quince Therapeutics, Inc. | 2025-08-01 | Phase 3 | NCT06193200 | Evaluate the Neurological Effects of EryDex on Subjects With A-T |
| URGN | UroGen Pharma Ltd. | 2025-08-01 | Phase 3 | NCT06331299 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer |
| XENE | Xenon Pharmaceuticals Inc. | 2025-08-01 | Phase 3 | NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) |